Embecta Corp. (EMBC)
| Bid | 11.69 |
| Market Cap | 715.63M |
| Revenue (ttm) | 1.11B |
| Net Income (ttm) | 57.5M |
| EPS (ttm) | 0.99 |
| PE Ratio (ttm) | 12.43 |
| Forward PE | 4.04 |
| Analyst | Hold |
| Ask | 12.75 |
| Volume | 240,182 |
| Avg. Volume (20D) | 599,275 |
| Open | 12.18 |
| Previous Close | 12.19 |
| Day's Range | 12.02 - 12.43 |
| 52-Week Range | 10.10 - 21.48 |
| Beta | 1.18 |
About EMBC
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and...
Analyst Forecast
According to 3 analyst ratings, the average rating for EMBC stock is "Hold." The 12-month stock price forecast is $15, which is an increase of 21.85% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In FavourEmbecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected ...
